The Global Fund, PEPFAR, CIFF, and BMGF are collaborating to provide affordable access to lenacapavir for HIV prevention, aiming to reach at least 2 million people in three years. Gilead Sciences’ lenacapavir is showing promise in preventing new HIV infections and has been licensed for manufacturing in low- and lower-middle-income countries. The goal is to accelerate progress towards ending HIV/AIDS as a public health threat by 2030 through widespread access to this innovative treatment.
Full Article
Create Lasting Memories: Fun Christmas Traditions to Start This Year
Looking to start a new Christmas tradition? Consider wrapping Christmas-themed movies or books to randomly choose and enjoy each day, engaging in Christmas crafts with the family, or participating in a reverse advent calendar by donating items to charity. Other ideas include decorating Christmas cookies, buying or making an annual ornament, sleeping under the tree on Christmas Eve, and capturing festive photos on Christmas morning. At Caxton, daily fresh news is generated by humans, not...
Read more